Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized Neoantigen Vaccine/DC in Advanced Solid Tumors
NCT05749627Recruiting
- Sponsor
- First Affiliated Hospital of Nanchang University
- Start
- Apr 2023
- Primary completion
- Dec 2025
- Countries
- 1
01
Overview
Open-label, single-arm trial in advanced malignant solid tumor, sponsored by First Affiliated Hospital of Nanchang University. Primary endpoints: Progression-free survival, Overall response rate and 1 more. Started Apr 2023; status: recruiting.
02
Conditions
advanced malignant solid tumor
Beyond the preview
Go deeper on NCT05749627.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05749627.